转自：中国质量报 精工铸重器 质量强国家 ——记第五届中国质量奖提名奖获得者东方电气集团东方汽轮机有限公司 □ 祝 宇 熊纹玉 在我国能源装备制造业版图上，东方电气集团东方汽轮机有限公司（以下简称"东方汽轮机"）占据很重 要的位置。前不久，这家深耕能源装备领域59载的企业，凭借"技术+管理"双擎驱动的质量管理模式， 斩获第五届中国质量奖提名奖。这一荣誉不仅是对该企业高质量发展成果的认可，更折射出我国能源装 备制造业在质量强国战略指引下，从跟跑、并跑到领跑的进阶之路。 "4个基础模块筑牢管理根基，5个重点模块破解核心痛点，N个自主模块适配个性化需求，这套系统让 精益从口号变为可落地的行动。"李艳介绍，在生产环节，企业建立拉式计划管理体系与五大配套中 心，实现主要部套制造周期缩短30%，关键部套人均效率增长近50%，整体产能提升60%，项目按期交 付率超98%；在供应链环节，通过品类管控、全生命周期管理、数字化协同，打造高效协同的精益供应 链体系，保障采购进度与质量稳定；在班组建设中，以"军、校、家"理念培育特色班组，公司承办的全 国机械冶金建材行业职工创新成果暨班组建设交流会，吸引110家企业的220余名代表观 ...

贝壳执行董事、首席财务官徐涛表示"今年三季度我们在主动优化业务结构、强化科技赋能等维度上取 得巨大进展，同时我们也在以更高强度践行股东回报承诺。当行业进入高质量发展新阶段时，兼具科技 创新、抗周期业务组合和精益运营经营体系的我们，必将为客户和投资者创造更大价值。" 11月10日，贝壳（NYSE:BEKE;HKEX:2423）发布2025年第三季度财务业绩。报告期内，贝壳总交易额 （GTV）7367亿元人民币，净收入231亿元人民币，同比增长2.1%，净利润7.47亿元人民币，经调整净 利润12.86亿元人民币。截至三季度末，贝壳剔除客户备付金的广义现金余额维持在约700亿元人民币。 在取得稳健业绩的同时，贝壳进一步加大股东回报力度。三季度回购金额达2.8亿美元，金额较去年同 期增长38.3%，创近两年来新高。 2025年至三季度末，贝壳累计回购总金额较去年同期提升15.7%。自2022年9月启动回购计划以来，截 至2025年9月30日，贝壳已累计回购约23亿美元，累计回购股数占启动前总股本约11.5%。 ...

Core Insights - WuXi AppTec reported strong financial results for Q3 2025, with total revenue of 12.06 billion yuan, a year-on-year increase of 15.3%, and a 19.7% growth in revenue from continuing operations [1] - The adjusted Non-IFRS net profit reached 4.22 billion yuan, reflecting a 42.0% year-on-year increase, and the total order amount for continuing operations hit a record high of 59.9 billion yuan [1] - The company raised its full-year revenue guidance to 43.5-44 billion yuan, indicating robust growth momentum [1] Financial Performance - The adjusted Non-IFRS net profit margin reached 32.1%, up 5.6 percentage points year-on-year, marking a historical high [2] - The chemical business segment saw an adjusted Non-IFRS gross margin increase to 51.3%, a significant rise of 5.8 percentage points [2] - The laboratory analysis and testing business improved its gross margin through differentiated capabilities and refined operational management [2] Operational Efficiency - WuXi AppTec's unique CRDMO business model and continuous operational improvements are key to its competitive advantage [3] - Operating cash flow for the reporting period was 10.87 billion yuan, a 35.0% year-on-year increase, providing a solid financial foundation for future investments [3] - The company has established a virtuous cycle of high-quality growth driven by excellent operations [3] Lean Operations - The company's lean operations have led to quantifiable efficiency improvements, with a 32% increase in data processing efficiency in the biological platform [4] - The identification software for nucleic acid and peptide metabolites improved project delivery efficiency by 33% [4] - The ramp-up time for new production facilities has been significantly reduced from 22.6 months in 2017 to 2.4 months in 2024, showcasing nearly a 90% efficiency improvement [4] Digital Transformation - WuXi AppTec has developed a comprehensive digital system with over 90 applications to enhance operational efficiency across R&D, production, and business operations [5] - The intelligent scheduling program has improved workshop utilization from 60% in 2020 to 72% currently, equivalent to "building" eight additional workshops without significant capital expenditure [5] Quality Management - The company integrates high-quality standards into its operational processes, achieving a near-zero error rate in production [6][7] - WuXi AppTec has successfully passed over 140 audits by global regulatory agencies since 2009, earning trust from clients and regulators [7] - The company recently achieved "zero defects" in FDA inspections at its Changzhou and Taixing facilities, reaffirming its commitment to the highest quality standards [7] Global Expansion - WuXi AppTec's lean operations are embedded in its CRDMO platform, facilitating rapid growth in the peptide and oligonucleotide sectors [8] - The company has established a global CRDMO service network with over 20 bases across Asia, Europe, and North America, and is expanding into the Middle East [8] - WuXi AppTec has returned value to shareholders through cash dividends totaling 4.88 billion yuan and a 2 billion yuan A-share buyback [8] Strategic Outlook - The company's strong quarterly performance demonstrates its strategic focus on lean operations as a core competency, enhancing its long-term competitiveness and growth potential [9]

Core Insights - The company reported lower-than-expected profits for Q3 2025, with revenue of 3.483 billion yuan, a year-on-year increase of 2.75%, and a net profit of 191 million yuan, down 14.83% year-on-year [1] - The decline in profits is attributed to tariff disruptions and weak terminal demand, with Q3 2025 revenue at 1.294 billion yuan, a year-on-year decrease of 3.26%, and a net profit of 59 million yuan, down 40.15% year-on-year [1] Financial Performance - For Q3 2025, the company's gross margin was 20.46%, down 1.96 percentage points year-on-year, and the net margin was 4.53%, down 2.93 percentage points year-on-year [2] - The company aims to improve profitability through lean operations and cost reduction, as terminal demand in the U.S. is expected to improve [2] Market Strategy - The company is actively expanding into non-U.S. markets and enhancing insights into top customers to mitigate trade friction risks [3] - Efforts include establishing multiple sales offices in key markets and accelerating the development of its own brand to boost domestic sales [3] Product Development - The company focuses on product leadership and continuous R&D innovation, launching the FLOW550T ergonomic chair series, which has received positive consumer feedback [2] - The company is enhancing its design capabilities and expanding its product matrix to improve aesthetic appeal [2] Future Outlook - Despite short-term pressure on export revenue due to external tariff impacts and weak terminal consumption, the company expects domestic brand sales to grow rapidly [4] - The forecast for net profit has been adjusted to 295 million yuan for 2025, 396 million yuan for 2026, and 491 million yuan for 2027, with corresponding year-on-year changes of -0.4%, +34.2%, and +24.1% [4]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's performance in the first three quarters of 2025 showed a revenue of 3.483 billion yuan, a year-on-year growth of 2.75%, while the net profit attributable to the parent company was 191 million yuan, down 14.83% year-on-year [6] - External environmental factors are gradually improving, and revenue growth is expected to recover as orders improve [6] - The company is focusing on product innovation and expanding its non-US market presence to mitigate external shocks [6][9] - The company aims to accelerate its brand building and domestic sales growth through various marketing strategies [6][9] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 5.095 billion yuan, with a year-on-year growth rate of 7.3% [5] - Net profit attributable to the parent company for 2025 is estimated at 295 million yuan, a slight decrease of 0.4% year-on-year [5] - The company’s gross margin for Q3 2025 was 20.46%, down 1.96 percentage points year-on-year, while the net margin was 4.53%, down 2.93 percentage points year-on-year [6] - The report projects a net profit of 396 million yuan for 2026 and 491 million yuan for 2027, with corresponding year-on-year growth rates of 34.2% and 24.1% respectively [5][8]

Core Viewpoint - Chihong Zn & Ge Co., Ltd. has demonstrated significant growth in its financial performance for the third quarter of 2025, with a notable increase in revenue and cash flow, indicating a strong operational foundation for future development [1][2]. Financial Performance - In Q3 2025, Chihong Zn & Ge achieved an operating revenue of 6.597 billion yuan, a substantial increase of 36.73% compared to the same period last year [1]. - For the first three quarters, the cumulative operating revenue reached 17.178 billion yuan, reflecting a year-on-year growth of 17.24% [1]. - The net cash flow from operating activities in Q3 was 1.249 billion yuan, marking a year-on-year increase of 27.46% [1]. - The cumulative net cash flow for the first three quarters grew by 31.96% year-on-year [1]. Operational Efficiency - The significant improvement in cash flow indicates enhanced operational efficiency, particularly in cost control, accounts receivable management, and overall operational system optimization [1]. - This financial strength provides a solid foundation for the company to navigate market fluctuations and support future growth [1]. Product Structure Optimization - Chihong Zn & Ge is actively optimizing its product structure, with high-value-added product output showing rapid growth [2]. - In the first three quarters, the production of lead and zinc smelting products increased by 1.06%, while zinc alloy production rose by 18.48% year-on-year [2]. - Silver product output, a key pillar for diversified profitability, grew by 29.62% year-on-year, enhancing the company's revenue sources and risk resilience [2]. Innovation and R&D Investment - The company invested 98.6284 million yuan in R&D during the reporting period, representing a year-on-year increase of 21.54% [2]. - This investment reflects a strong commitment to technological innovation, process upgrades, and new product development, reinforcing the company's long-term competitive advantage [2].

Core Insights - The report from CITIC Construction Investment forecasts Luoyang Molybdenum's net profit for 2025-2027 to be CNY 19.989 billion, CNY 24.800 billion, and CNY 27.928 billion respectively, with corresponding PE ratios of 16.28, 13.12, and 11.65 based on current stock prices [1] Group 1: Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of CNY 145.485 billion and a net profit attributable to shareholders of CNY 14.280 billion, marking a year-on-year increase of 72.61%, setting a new historical high for the same period and surpassing the total for the previous year [1] - In Q3 2025, the company reported a net profit attributable to shareholders of CNY 5.608 billion [1] Group 2: Production and Projects - The company reported significant increases in production for copper, cobalt, molybdenum, tungsten, niobium, and phosphate fertilizer in the first three quarters of 2025, with copper production reaching 543,400 tons, a year-on-year increase of 14.14%, setting a new historical high for the same period [1] - The company plans to invest up to USD 1.084 billion in the construction of the KFM Phase II project, which is progressing steadily [1] Group 3: Market Conditions - In Q3 2025, the average LME copper spot price increased by 2.9% from Q2 to USD 9,797 per ton, while prices for cobalt, molybdenum, iron, APT, niobium, and monoammonium phosphate saw increases of 11.4%, 18.0%, 38.9%, 3.4%, and 0.6% respectively [1] - The company has received the largest export quota from the government of the Democratic Republic of the Congo, allowing for an export volume of 6,500 tons for the remainder of 2025, which accounts for 35.9% of the total quota [2] - The tightening supply in the cobalt market is expected to maintain high price levels, with future export volumes limited to 96,600 tons over the next two years, a reduction of approximately 100,000 tons [2]

Core Insights - The core viewpoint of the article emphasizes the strong financial performance and strategic focus of WuXi AppTec, particularly its integrated CRDMO model, which has driven significant revenue growth and established a solid competitive advantage in the biopharmaceutical industry [1][10]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of RMB 32.86 billion, representing a year-on-year growth of 18.6%. The revenue from its core operations grew by 22.5% [1]. - The company has raised its guidance for the full-year revenue growth of core operations to 17%-18%, with an overall revenue expectation adjusted to RMB 43.5 billion to RMB 44 billion [1]. - The gross margin exceeded 46%, and the adjusted profit margin surpassed 36%. The net cash flow from operating activities reached RMB 11.413 billion, a 36.21% increase year-on-year [4]. Strategic Focus - WuXi AppTec's strategic focus on the integrated CRDMO model is highlighted as a key driver of its long-term value creation, emphasizing the importance of making difficult yet correct strategic decisions [2][10]. - The company has divested non-core businesses, such as ATU (cell and gene therapy), to concentrate resources on its CRDMO mainstay, reinforcing its competitive position [4]. Operational Efficiency - The company has significantly improved its operational efficiency, reducing the time required for a new workshop to reach full production from 22.6 months in 2017 to just 2.4 months in 2024 [7]. - WuXi AppTec has implemented a self-developed digital system, the Pyxis intelligent scheduling system, which has increased equipment utilization from 60% to 72%, effectively enhancing production efficiency [8]. - The "Eagle Eye System" has minimized human error rates in drug production to 0.05 per 2000 batches, ensuring high-quality standards and reliability [9]. Growth Drivers - As of September 2025, the company had a backlog of RMB 59.88 billion in ongoing business orders, reflecting a robust growth foundation for the upcoming quarters [2]. - The TIDES business (oligonucleotides and peptides) generated revenue of RMB 7.84 billion, marking a year-on-year increase of 121.1%, indicating the successful establishment of a "second growth curve" [3]. Market Position and Future Outlook - The company’s unique integrated CRDMO model, proactive new business layouts, and strong global customer base are identified as the pillars of its fundamental growth [10]. - The ongoing global expansion, including capacity building in the U.S., Singapore, and Switzerland, positions the company to better meet global client demands and mitigate geopolitical risks [10][11].

Group 1: Acquisition and Market Strategy - The acquisition of BATAVIA B.V. aims to leverage its product design capabilities and local sales channels to create a comprehensive "R&D-design-manufacturing-marketing" synergy, establishing a strong foothold in overseas markets [1][2] - Post-acquisition, the company enhances BATAVIA B.V. with its manufacturing capabilities, cost control systems, and stable supply chain, enabling it to respond quickly to orders and deliver high-quality products, thus expanding market coverage [1][2] Group 2: Internal and External Supply Chain - The subsidiary, Pucheng Electronics, established in 2023, has developed a specialized production facility and advanced equipment, enabling it to serve both internal and external markets effectively [3] - Internally, Pucheng Electronics meets customized needs of the group, while externally, it has successfully entered the supplier systems of major clients like Stanley Black & Decker and Makita, creating a dual-channel business model [3] Group 3: Production Capacity and Operations - The Thai subsidiary is currently ramping up production capacity and is expected to reach full capacity by the end of the year, benefiting from the company's production, technology, talent, and quality advantages [4] - The company maintains a dynamic alignment between personnel size and business development needs, avoiding significant increases in staff numbers despite business expansion, thanks to automation and smart management systems [6][7] Group 4: Share Repurchase and Employee Incentives - The company has completed its share repurchase plan, with shares to be used for employee stock ownership or incentive plans, adhering to relevant legal and disclosure requirements [5]

Core Insights - Luoyang Molybdenum's Q3 report shows record high net profit of 14.28 billion yuan, a 72.61% year-on-year increase, surpassing last year's total [2] - The company achieved a single-quarter profit of 5.61 billion yuan in Q3, marking a 96.40% increase year-on-year [2] - The basic earnings per share reached 0.67 yuan, with operating cash flow of 15.86 billion yuan [2] Revenue and Production - Total revenue for the first three quarters reached 145.49 billion yuan, with copper revenue contributing 38.6% [2] - Copper production increased by 14.14% to 543,400 tons, achieving 86.25% of the annual target [2] - The cobalt, molybdenum, tungsten, niobium, and phosphate production exceeded planned targets, with cobalt production at 88,000 tons [3] Cost Management and ESG Performance - The company's operating costs decreased by 10.94% year-on-year, indicating effective cost management [3] - Luoyang Molybdenum maintained an AA rating in MSCI ESG performance for three consecutive years, ranking in the top 11% of the non-ferrous metals industry [3] Future Projects and Investments - The company announced a $1.084 billion investment for the KFM mine phase II, expected to produce an additional 100,000 tons of copper annually starting in 2027 [3] - Ongoing construction of the Heshima hydropower station in the Democratic Republic of Congo aims to secure local electricity supply [3] Management Changes - Luoyang Molybdenum appointed Peng Xuhui as President and CEO, and Branko Buhavac as Vice President and Chief Commercial Officer [4] - The company aims to enhance operational efficiency and attract global talent through a stock incentive plan of 393 million shares [4]